An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05505916 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: KVD900 600 mg
DRUG: KVD900 300 mg

Sponsor

KalVista Pharmaceuticals, Ltd.